1. Volume 64, Issue 5, Pages 1090-1098 (May 2016)
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial 
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, Maria Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, Luis Ruiz del Arbol, Marie-Aude Leberre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix 
Journal of Hepatology 
Volume 64, Issue 5, Pages (May 2016)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Trial profile.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Efficacy outcomes in patients in the SPACE trial randomized to sorafenib or placebo plus DEB-TACE. A) Time-to-progression (TTP) by blinded central review, B) time to macrovascular invasion/extrahepatic spread (MVI/EHS), C) overall survival (OS), and D) time to unTACEable progression (TTUP) by investigator assessment. NR, not reached.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions